Dylan Kornbluth

Cooley advised Drata, a trust management platform, on its definitive agreement to acquire SafeBase, a trust center platform designed for friction-free security reviews.

Cooley advised Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets, on its sale to Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, for up to $1.3 billion.

Cooley advised TriSalus Life Sciences, an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, on the closing of its previously announced exchange offer and consent solicitation for special purpose acquisition company warrants. Partner Matt Browne led the Cooley team advising TriSalus.

Cooley advised TriSalus Life Sciences, an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, on the closing of a debt financing facility for up to $50 million with OrbiMed. Partners Mischi a Marca and Matt Browne led the Cooley team advising TriSalus.

Cooley advised Morphimmune, a private biotechnology company, in its definitive merger agreement with Immunome and $125 million private investment.